NOD-like Receptor (NLR) Inhibitor

Forsythoside I (Standard) is the analytical standard of Forsythoside I (HY-N5042). This product is intended for research and analytical applications. Forsythoside I is an orally active caffeoyl phenylethanoid glycoside (CPG) that can be isolated from Forsythia suspense (Thunb.) Vahl. Forsythoside I has anti-inflammatory activity and can exert a protective effect in a mouse model of acute lung injury.

INF200 (compound 5) is a sulfonylurea-based inhibitor of NLRP3 and NLRP3-mediated pyroptosis. INF200 has beneficial cardiometabolic effects in rat model of high-fat diet (HFD)-induced metaflammation，and shows anti-inflammatory activity to (10 μM) decreases IL-1β release in human macrophages. INF200 improves glucose and lipid profiles，and attenuates systemic inflammation and biomarkers of cardiac dysfunction (particularly BNP). INF200 also improves myocardial damage-dependent ischemia/reperfusion injury (IRI) in hemodynamic evaluation.

CY-09 (Standard) is the analytical standard of CY-09 (HY-103666). This product is intended for research and analytical applications. CY-09 is a selective and direct NLRP3 inhibitor. CY-09 directly binds to the ATP-binding motif of NLRP3 NACHT domain and inhibits NLRP3 ATPase activity, resulting in the suppression of NLRP3 inflammasome assembly and activation.

NLRP3-IN-28 (compound N77) is a potent inhibitor of NLRP3. NLRP3-IN-28 inhibits Nigericin (HY-127019)-induced pyroptosis with an EC₅₀ of 0.07μM. NLRP3-IN-28 alleviates the inflammatory reaction in vivo.

DPO-1 (Standard) is the analytical standard of DPO-1 (HY-100712). This product is intended for research and analytical applications. DPO-1 is a potent Kv1.5 and Kv1.3 (EC50 = 3.1 μM) channels inhibitor with potential immunomodulatory and anti-inflammatory effects. DPO-1 reduces Kv1.3 current density, blunts Ca2+ influx in Ca2+-depleted Jurkat cells, and inhibits IL-2 secretion in activated Jurkat cells. DPO-1 inhibits Uric acid sodium (HY-B2130A) (MSU)-induced NLRP3 inflammasome activation by blocking Kv1.5-mediated K+ efflux. DPO-1 can be used for the study of immunologic disorders and atrial fibrillation.

Maresin 2-d₅ is the d₅-labeled Maresin 2 (HY-119684). Maresin 2 is an anti-inflammatory and pro-resolving mediator. Maresin 2 drives intestinal epithelial cell migration by activating the focal cell-matrix adhesion signaling pathway in primary human intestinal epithelial cells, thereby promoting mucosal wound repair. Maresin 2 alleviates nociceptive and anxiety-like behaviors in rats with type 1 diabetes by inhibiting IL-1β in the spinal cord and prefrontal cortex. Maresin 2 attenuates allergic airway inflammation in mice by inhibiting the activation of the NLRP3 inflammasome, Th2-type immune responses, and oxidative stress. Maresin 2 inhibits inflammatory and neuropathic trigeminal neuralgia and reduces neuronal activation in the trigeminal ganglion. Maresin 2 promotes inflammation resolution and mucosal repair after DSS-induced colitis or biopsy-induced colonic mucosal injury.

p-Ethoxychrysoidin is a benzotriazole-based NLRP3 inhibitor. p-Ethoxychrysoidin can be used in research on inflammatory diseases and neurodegenerative diseases.

Garlic oil is an orally effective anti-inflammatory, antioxidant, and anticancer agent. Garlic oil inhibits the activation of NF-κB, NFκB2 and NLRP3 inflammasome, and induces the expression of GSTA1, HO-1 and NQO-1. Garlic oil reduces the Bcl-2/Bax protein ratio and activates NNK-induced apoptosis (apoptosis) in lung tissues. Garlic oil attenuates NNK-induced apoptosis in MRC-5 cells and reduces excessive ROS production. Garlic oil alleviates pyroptosis (pyroptosis) and exerts a protective effect against acute lung injury in mice. Garlic oil inhibits lung tumorigenesis in mice and improves small intestinal motility in rats with type 2 diabetes. Garlic oil can be used in research related to acute lung injury, lung cancer, peptic ulcer, type 2 diabetes and hypertension.

3-Et-3TC (Page 87, Compound 3b) is a structurally modified derivative of Lamivudine (HY-B0250). 3-Et-3TC can inhibit the activation of the NLRP3 inflammasome and can be used for the study of retinal degenerative diseases.

NLRP3-IN-95 is an NLRP3 inflammasome inhibitor with an IC₅₀ of 27 nM. NLRP3-IN-95 inhibits IL-1β secretion in PMA-differentiated THP-1 cells. NLRP3-IN-95 can be used in studies related to acute monocytic leukemia and inflammatory diseases.